The Lower-Back Painkiller Challenge: Efficacy of Tramadol Versus Tapentadol


  • Naveed Gul
  • Kashif Ramooz
  • Yasir Shehzad
  • Soban Sarwar Gondal
  • Fraz Mehmood
  • Hafiz Muhammad Ali Khan
  • Eesha Yaqoob
  • Saad Javed



Introduction:  To reduce pain levels in people with lower back pain, the study looked at the comparative efficacy and tolerability of Tramadol and Tapentadol taken by oral route.

Materials & Methods:  This comparative study consisted of a total of 126 patients divided into 2 groups, the Tapentadol and Tramadol groups for managing low back pain. Participants aged 18-60 with moderate or higher pain intensity were included. Data on pain intensity, adverse events, and patient-reported outcomes were collected at baseline, day 7, and day 14. Participants were randomly assigned to Tapentadol or Tramadol groups, receiving respective medications for 14 days. Data analysis involved t t-test to compare groups. Means and SD were also calculated.

Results:  The mean age of the patients in the Tramadol group was 33.1 ± 19.1 and in the Tapentadol group was 37.6 ± 19.9, respectively. Sixty of the total participants were men and sixty-five were women. Participants were split equally between groups A and B, with 30 men and 33 women in group A and 30 men and 32 women in group B. The findings demonstrated that both medications considerably lessened moderate to severe chronic lower back pain (CLBP) patients' pain levels. At 28 days after the baseline, the mean VAS scores for groups A and B were 34.57 and 37.55, respectively. 

Conclusion:  According to the study's findings, these two medications effectively reduce pain in those with chronic lower back pain. Tapentadol is observed to be tolerated well and more effective than Tramadol.



Serranheira F, Sousa-Uva M, Heranz F, Kovacs F, Sousa-Uva A. Low Back Pain (LBP), work and absenteeism. Work, 2020;65(2):463-9.

Chitale Jr N, Patil DS, Phansopkar P, Joshi A, Chitale NV, Patil Sr DS. A Review on Treatment Approaches for Chronic Low Back Pain via Mulligans Movement With Mobilization and Physical Therapy. Cureus, 2022;14(8).

Hoy D, Bain C, Williams G, March L, Brooks P, Blyth F, Woolf A, Vos T, Buchbinder R. A systematic review of the global prevalence of low back pain. Arthritis & rheumatism, 2012;64(6):2028-37.

Ochsenkuehn FR, Crispin A, Weigl MB. Chronic low back pain: a prospective study with 4 to 15 years follow-up after a multidisciplinary biopsychosocial rehabilitation program. BMC Musculoskeletal Disorders, 2022;23(1):977.

Liu K, Zhang Q, Chen L, Zhang H, Xu X, Yuan Z, Dong J. Efficacy and safety of extracorporeal shockwave therapy in chronic low back pain: a systematic review and meta-analysis of 632 patients. Journal of Orthopaedic Surgery and Research, 2023;18(1):1-7.

Chou R, Deyo R, Friedly J, Skelly A, Hashimoto R, Weimer M, Fu R, Dana T, Kraegel P, Griffin J, Grusing S. Nonpharmacologic therapies for low back pain: a systematic review for an American College of Physicians clinical practice guideline. Annals of internal medicine, 2017;166(7):493-505.

Migliorini F, Maffulli N, Baroncini A, Eschweiler J, Tingart M, Quack V. Opioids for chronic low back pain management: a Bayesian network meta-analysis. Expert Review of Clinical Pharmacology, 2021;14(5):635-41.

Lynch ME, Watson CP. The pharmacotherapy of

chronic pain: a review. Pain Research and Management, 2006;11:11-38.

Dowell D, Haegerich TM, Chou R. CDC guideline for prescribing opioids for chronic pain—United States, 2016. Jama. 2016;315(15):1624-45.

Ketenci A, Zure M. Pharmacological and non-pharmacological treatment approaches to chronic lumbar back pain. Turkish journal of physical medicine and rehabilitation, 2021;67(1):1.

Gudin J, Kaufman AG, Datta S. Are opioids needed to treat chronic low back pain? A review of treatment options and analgesics in development. Journal of Pain Research, 2020:1007-22.

Dowell D, Haegerich TM, Chou R. CDC guideline for prescribing opioids for chronic pain—United States, 2016. Jama. 2016;315(15):1624-45.

Buckwalter JA, Saltzman C, Brown T. The impact of osteoarthritis: implications for research. Clinical Orthopaedics and Related Research (1976-2007). 2004;427:S6-15.

Srikanth VK, Fryer JL, Zhai G, Winzenberg TM, Hosmer D, Jones G. A meta-analysis of sex differences prevalence, incidence and severity of osteoarthritis. Osteoarthritis and cartilage, 2005;13(9):769-81.

Tetsunaga T, Tetsunaga T, Tanaka M, Ozaki T. Efficacy of tramadol–acetaminophen tablets in low back pain patients with depression. Journal of Orthopaedic Science. 2015;20(2):281-6.

April KT, Bisaillon J, Welch V, Maxwell LJ, Jüni P, Rutjes AW, Husni ME, Vincent J, El Hindi T, Wells GA, Tugwell P. Tramadol for osteoarthritis. Cochrane database of systematic reviews. 2019(5).

Mercier F, Claret L, Prins K, Bruno R. A model-based meta-analysis to compare efficacy and tolerability of tramadol and tapentadol for the treatment of chronic non-malignant pain. Pain and therapy, 2014 Jun;3:31-44.

Wade WE, Spruill WJ. Tapentadol hydrochloride: a centrally acting oral analgesic. Clinical therapeutics, 2009;31(12):2804-18.

Walczyk H, Liu CH, Alafris A, Cohen H. Probable tapentadol-associated serotonin syndrome after overdose. Hospital pharmacy, 2016;51(4):320-7.

Kress HG, Coluzzi F. Tapentadol in the management of cancer pain: current evidence and future perspectives. Journal of pain research, 2019:1553-60.

Boya C, Bansal D, Kanakagiri S, Ghai B. Efficacy and safety of opioid analgesics for the management of chronic low back pain: an evidence from Bayesian network meta-analysis. Pain Physician, 2021;24(1):73.






Original Articles